Clinical trials: Systemic Sclerosis, Diffuse
Interstitial Lung Disease, Connective Tissue Disease
A Clinical Trial for CTD-ILD Treatment
The first objective of this protocol is to assess the tolerability and safety of N-acetylcysteine (NAC) in patients with connective tissue disease related interstitial lung disease (CTD-ILD).
- Trial name
- NCT01424033
- Testing
- N-Acetylcysteine
- Where
- United States
- Volunteers
- 5 people
- Sponsor
- University of Michigan
Systemic Sclerosis, Scleroderma
Scleroderma Registry
Scleroderma is likely caused by a combination of factors, including an external trigger (infection or other exposure) and a genetic predisposition.
- Trial name
- Registry (NCT00074568)
- Where
- United States
- Volunteers
- 5,000 people, healthy volunteers welcome
- Sponsor
- National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)
Digital Ulcer of Scleroderma
Diltiazem Gel Versus Nitroglycerin Ointment in Healing Process of Scleroderma Digital Ulcers
Digital ulcers are one of the most prevalent complications of scleroderma (systemic sclerosis). There can be found few surveys on effect of topical agents on healing process of the ulcers.
- Trial name
- NCT02801305
- Testing
- Diltiazem Gel 2%, Nitroglycerin Ointment 2%, Vaseline
- Where
- Iran
- Volunteers
- 90 people
- Sponsor
- Mohammad Ali Nazarinia
Early Diffuse Cutaneous Systemic Sclerosis
Treatment Outcome in Early Diffuse Cutaneous Systemic Sclerosis
The aim of the study is to compare the effectiveness of commonly used immunosuppressant treatments for early diffuse cutaneous systemic sclerosis (SSc).
- Trial name
- ESOS (NCT02339441)
- Testing
- Methotrexate, Mycophenolate mofetil, Cyclophosphamide
- Volunteers
- 320 people
- Sponsor
- University of Manchester
Systemic Sclerosis, Pulmonary; Hypertension
Dimethyl Fumarate (DMF) in Systemic Sclerosis-Associated Pulmonary Arterial Hypertension
A double-blinded, placebo-controlled study of Dimethyl fumarate (DMF) in 34 Systemic Sclerosis-Pulmonary Hypertension (SSc-PAH) patients.
- Trial name
- NCT02981082
- Testing
- Dimethyl Fumarate (DMF)
- Where
- 4 sites in United States
- Volunteers
- 6 people
- Sponsor
- Robert Lafyatis
Systemic Sclerosis, Scleroderma
Calcinosis Reduction by Pyrophosphate in SSC
Calcinosis, i.e. crystal-like nodules are troublesome complication of systemic sclerosis, an autoimmune disease. Pyrophosphate inhibits its formation is laborytory.
- Trial name
- NCT04966416
- Testing
- Pyrophosphate
- Volunteers
- 60 people
- Sponsor
- Szeged University
Gastroesophageal Reflux Disease, Systemic Sclerosis
Gastroesophageal Reflux Treatment in Scleroderma
The investigators purposes are to define the prevalence of omeprazole resistance gastroesophageal reflux disease (GERD) in systemic sclerosis (SSc), to compare the efficacy of omeprazole in combination with algycon versus…
- Conditions
- Gastroesophageal Reflux Disease, Systemic Sclerosis, Scleroderma
- Trial name
- GERD-SSc (NCT01878526)
- Testing
- Alginic acid, Domperidone
- Where
- Thailand
- Volunteers
- 80 people
- Sponsor
- Khon Kaen University
Systemic Sclerosis
Recombinant Human Relaxin in the Treatment of Diffuse Scleroderma
Relaxin is a naturally occurring protein prduced by the ovary or placenta in pregnancy. It has ani-fibrotic properties. Previous studies have shown that relaxin is safe at concentrations upto 60 times higher than achieved in…
- Trial name
- NCT00704665
- Testing
- Relaxin
- Volunteers
- 231 people
- Sponsor
- University of Medicine and Dentistry of New Jersey
Systemic Lupus Erythematosus, Scleroderma
Efficacy and Safety of HN2301 in Autoimmune Diseases（AIDs）
This is an open lable and single arm study, is designed to evaluate the safety and preliminary efficacy of HN2301 in Autoimmune Disease（AID）
- Conditions
- Systemic Lupus Erythematosus, Scleroderma, Rheumatoid Arthritis
- Trial name
- SLE，SSc，RA (NCT06801119)
- Testing
- HN2301 injection
- Where
- China
- Volunteers
- 30 people
- Sponsor
- Shenzhen MagicRNA Biotechnology Co., Ltd
Scleroderma, Digital Ulcers
Riociguat in Scleroderma Associated Digital Ulcers
The primary objective of this study is to provide preliminary data on the efficacy (digital ulcer net burden) and safety of riociguat administered 3 times daily (TID) in comparison to placebo in patients with…
- Trial name
- RESCUE (NCT02915835)
- Testing
- Riociguat
- Where
- 5 sites in United States
- Volunteers
- 17 people
- Sponsor
- Dinesh Khanna, MD, MS
Diffuse Cutaneous Systemic Sclerosis
Efficacy and Safety of IgPro10 in Adults With Systemic Sclerosis (SSc)
This randomized, multicenter, double-blind (DB), placebo controlled, phase 2 study will evaluate the efficacy and safety of IgPro10. The DB Treatment Period will be followed by a 24-week Open-label (OL) Treatment Period.
- Trial name
- NCT04138485
- Testing
- IgPro10
- Where
- 77 sites in United States, Argentina and 11 more
- Sponsor
- CSL Behring
Scleroderma, Diffuse, Diffuse Cutaneous Systemic Sclerosis
Proof-of-concept Trial of IVA337 in Diffuse Cutaneous Systemic Sclerosis
Systemic sclerosis (SSc), or scleroderma is a connective tissue disease of autoimmune origin. It is a life-threatening orphan disease with severe physical and psychosocial consequences.
- Trial name
- FASST (NCT02503644)
- Testing
- IVA337
- Where
- 49 sites in Bulgaria, France and 8 more
- Volunteers
- 145 people
- Sponsor
- Inventiva Pharma
Scleroderma, Systemic Sclerosis
IL1-TRAP, Rilonacept, in Systemic Sclerosis
Scleroderma,also known as systemic sclerosis (SSc), is a multisystem disease affecting skin and other tissues including joints, muscles, lungs, the gastrointestinal tract and kidneys and tissue fibrosis is widespread.
- Conditions
- Scleroderma, Systemic Sclerosis, Diffuse Scleroderma, Diffuse Systemic Sclerosis
- Trial name
- NCT01538719
- Testing
- Rilonacept
- Where
- United States
- Volunteers
- 24 people
- Sponsor
- Boston University
Pulmonary Hypertension
Endothelial Function in Patients With Scleroderma or Cirrhosis With and Without Pulmonary Hypertension
Pulmonary arterial hypertension (PAH) is a condition characterized by an increased pulmonary vascular resistance that can lead to right heart failure and death.
- Trial name
- NCT01729611
- Where
- United States
- Volunteers
- 119 people
- Sponsor
- The Cleveland Clinic
Systemic Sclerosis (SSc), Scleroderma
6-minute Pegboard Ring Test in Patients With Scleroderma
The aim of this observational study was to evaluate the reliability and validity of the 6-minute pegboard and ring test (6PBRT) in patients with systemic sclerosis.
- Trial name
- NCT06588959
- Testing
- validity and reliability study
- Where
- Turkey (Türkiye)
- Volunteers
- 50 people
- Sponsor
- Yasemin GEDIKLI
Keloid, Scleroderma, Localized
Ultraviolet B (UVB) Light Therapy in the Treatment of Skin Conditions With Altered Dermal Matrix
This research study will evaluate the effectiveness of high dose UVB light therapy in the treatment of keloid (or hypertrophic scar), scleroderma, acne keloidalis nuchae, old burn scars, granuloma annulare or related conditions.
- Conditions
- Keloid, Scleroderma, Localized, Acne Keloidalis, Scars
- Trial name
- NCT00129428
- Testing
- UVB Irradiation
- Where
- United States
- Volunteers
- 33 people
- Sponsor
- University of Michigan
Scleroderma
Respiratory Muscle Strength and Aerobic Capacity in Scleroderma
Primary aim of this study was to compare respiratory muscle strength, aerobic capacity, dyspnea, pulmonary function tests and fatigue values with healthy controls.
- Trial name
- NCT06554132
- Testing
- Scleroderma Group, Healthy group
- Where
- Turkey (Türkiye)
- Volunteers
- 15 people, healthy volunteers welcome
- Sponsor
- Firat University
Systemic Sclerosis, Scleroderma
Evaluation of Tofacitinib in Early Diffuse Cutaneous Systemic Sclerosis (dcSSc)
This Phase I/II placebo controlled trial will evaluate tofacitinib in subjects with diffuse cutaneous systemic scleroderma (dcSSc).
- Trial name
- TOFA-SSc (NCT03274076)
- Testing
- Tofacitinib
- Where
- 2 sites in United States
- Volunteers
- 15 people
- Sponsor
- University of Michigan
Raynaud's Phenomenon Secondary to Systemic Sclerosis
Study of Acute Peripheral Vascular Effects, Safety and Tolerability in Subjects With Raynaud's Phenomenon Secondary to Systemic Sclerosis
The purpose of this study is to evaluate pharmacodynamics (PD) in adult subjects with a diagnosis of Raynaud's Phenomenon secondary to Systemic Sclerosis (SSc).
- Trial name
- NCT02228850
- Testing
- Alprostadil
- Where
- 4 sites in United States
- Volunteers
- 35 people
- Sponsor
- NexMed (U.S.A.), Inc. (subsidiary of Apricus Biosciences, Inc.)
Scleroderma, Pulmonary Hypertension
Sleep Disturbances and Pulmonary Artery/Aorta Diameter in Scleroderma Patient
To determine sleep disturbance, pulmonary function test, 6 minute walk, echocardiogram abnormality, arterial blood gas, ventilation/perfusion scan of the chest in Scleroderma patient with Pulmonary Hypertension.
- Trial name
- Scleroderma (NCT00566137)
- Volunteers
- 50 people
- Sponsor
- Northwell Health